Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment
Open Access
- 30 December 2022
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (1) , 128
Abstract
Targeted radionuclide therapy (TRT) and immunotherapy are rapidly growing classes of cancer treatments. Basic, translational, and clinical research are now investigating therapeutic combinations of these agents. In comparison to external beam radiation therapy (EBRT), TRT has the unique advantage of treating all disease sites following intravenous injection and selective tumor uptake and retention—a particularly beneficial property in metastatic disease settings. The therapeutic value of combining radiation therapy with immune checkpoint blockade to treat metastases has been demonstrated in preclinical studies, whereas results of clinical studies have been mixed. Several clinical trials combining TRT and immune checkpoint blockade have been initiated based on preclinical studies combining these with EBRT and/or TRT. Despite the interest in translation of TRT and immunotherapy combinations, many questions remain surrounding the mechanisms of interaction and the optimal approach to clinical implementation of these combinations. This review highlights the mechanisms of interaction between anti-tumor immunity and radiation therapy and the status of basic and translational research and clinical trials investigating combinations of TRT and immunotherapies.Keywords
Funding Information
- NIH NCI (P01CA250972, F30CA268780, T32GM140935)
- National Institutes of Health (P01CA250972, F30CA268780, T32GM140935)
This publication has 84 references indexed in Scilit:
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- What is the Role of the Bystander Response in Radionuclide Therapies?Frontiers in Oncology, 2013
- Radioembolization in the Treatment of Unresectable Liver TumorsAmerican Journal of Clinical Oncology, 2012
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin LymphomaJournal of Nuclear Medicine, 2009
- Therapeutic Radionuclides: Biophysical and Radiobiologic PrinciplesSeminars in Nuclear Medicine, 2008
- -H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatinNucleic Acids Research, 2008
- The Use of Chelated Radionuclide (Samarium-153-Ethylenediaminetetramethylenephosphonate) to Modulate Phenotype of Tumor Cells and Enhance T Cell–Mediated KillingClinical Cancer Research, 2008
- Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate CancerJournal of Clinical Oncology, 2006
- STUDIES ON X-RAY EFFECTSJournal of Experimental Medicine, 1921